Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of American pathologists joint review

Journal of Clinical Oncology

Volumn 36, Issue 16, 2018, Pages 1631-1641

  Merker, Jason D ^a   Oxnard, Geoffrey R ^b   Compton, Carolyn ^d   Diehn, Maximilian ^a   Hurley, Patricia ^e   Lazar, Alexander J ^f   Lindeman, Neal ^c   Lockwood, Christina M ^g   Rai, Alex J ^h   Schilsky, Richard L ^e   Tsimberidou, Apostolia M ^f   Vasalos, Patricia ⁱ   Billman, Brooke L ⁱ   Oliver, Thomas K ^e   Bruinooge, Suanna S ^e   Hayes, Daniel F ^j   Turner, Nicholas C ^k  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

^e AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h NewYork Presbyterian Hospital   (United States)

ⁱ Molecular Pathology Division   (United States)

^j UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^k INSTITUTE OF CANCER RESEARCH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULATING TUMOR DNA; EDETIC ACID; DNA; TUMOR MARKER;

ADVANCED CANCER; CANCER PATIENT; CANCER SCREENING; DISEASE ACTIVITY; DNA DETERMINATION; EARLY CANCER; EARLY CANCER DIAGNOSIS; GENOTYPE; HUMAN; LIMIT OF DETECTION; LIQUID BIOPSY; MINIMAL RESIDUAL DISEASE; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; REVIEW; SOLID MALIGNANT NEOPLASM; SPECIMEN HANDLING; TREATMENT OUTCOME; TUMOR VOLUME; VALIDITY; BLOOD; BLOOD SAMPLING; GENETICS; GENOTYPING TECHNIQUE; MEDICAL SOCIETY; NEOPLASM; PROCEDURES; STANDARDS; UNITED STATES;

BIOMARKERS, TUMOR; BLOOD SPECIMEN COLLECTION; CIRCULATING TUMOR DNA; DNA, NEOPLASM; GENOTYPING TECHNIQUES; HUMANS; NEOPLASMS; SOCIETIES, MEDICAL; UNITED STATES;

EID: 85048218708     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.76.8671     Document Type: Review

References (93)

1. Pantel K, Alix-Panabieres C: Circulating tumour cells in cancer patients: Challenges and perspectives. Trends Mol Med 16:398-406, 2010
2. Dawson SJ, Tsui DW, Murtaza M, et al: Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368:1199-1209, 2013
3. Teutsch SM, Bradley LA, Palomaki GE, et al: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: Methods of the EGAPP Working Group. Genet Med 11:3-14, 2009
4. Micheel CM, Nass SJ, Omenn, GS (eds): Evolution of Translational Omics: Lessons Learned and the Path Forward. Washington, DC, National Academies Press, 2012
5. El Messaoudi S, Rolet F, Mouliere F, et al: Circulating cell free DNA: Preanalytical considerations. Clin Chim Acta 424:222-230, 2013
6. Bronkhorst AJ, Aucamp J, Pretorius PJ: Cellfree DNA: Preanalytical variables. Clin Chim Acta 450: 243-253, 2015
7. Lee TH, Montalvo L, Chrebtow V, et al: Quantitation of genomic DNA in plasma and serum samples: Higher concentrations of genomic DNA found in serum than in plasma. Transfusion 41: 276-282, 2001
8. Board RE, Wardley AM, Dixon JM, et al: Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat 120:461-467, 2010
9. Page K, Powles T, Slade MJ, et al: The importance of careful blood processing in isolation of cell-free DNA. Ann N Y Acad Sci 1075:313-317, 2006
10. Kang Q, Henry NL, Paoletti C, et al: Comparative analysis of circulating tumor DNA stability in K3EDTA, Streck, and CellSave blood collection tubes. Clin Biochem 49:1354-1360, 2016
11. Rothwell DG, Smith N, Morris D, et al: Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample. Mol Oncol 10: 566-574, 2016
12. Chan KC, Yeung SW, Lui WB, et al: Effects of preanalytical factors on the molecular size of cell-free DNA in blood. Clin Chem 51:781-784, 2005
13. Lam NY, Rainer TH, Chiu RW, et al: EDTA is a better anticoagulant than heparin or citrate for delayed blood processing for plasma DNA analysis. Clin Chem 50:256-257, 2004
14. van Dessel LF, Beije N, Helmijr JC, et al: Application of circulating tumor DNA in prospective clinical oncology trials: Standardization of preanalytical conditions. Mol Oncol 11:295-304, 2017
15. Medina Diaz I, Nocon A, Mehnert DH, et al: Performance of Streck cfDNA blood collection tubes for liquid biopsy testing. PLoS One 11:e0166354, 2016
16. Sherwood JL, Corcoran C, Brown H, et al: Optimised pre-analytical methods improve KRAS mutation detection in circulating tumour DNA (ctDNA) from patients with non-small cell lung cancer (NSCLC). PLoS One 11:e0150197, 2016
17. Toro PV, Erlanger B, Beaver JA, et al: Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. Clin Biochem 48: 993-998, 2015
18. Oxnard GR, Paweletz CP, Sholl LM: Genomic analysis of plasma cell-free DNA in patients with cancer. JAMA Oncol 3:740-741, 2017
19. Busser B, Lupo J, Sancey L, et al: Plasma circulating tumor DNA levels for the monitoring of melanoma patients: Landscape of available technologies and clinical applications. BioMed Res Int 2017:5986129, 2017
20. Bettegowda C, Sausen M, Leary RJ, et al: Detection of circulating tumor DNA in early- and latestage human malignancies. Sci Transl Med 6: 224ra24, 2014
21. Siravegna G, Marsoni S, Siena S, et al: Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 14:531-548, 2017
22. Higgins MJ, Jelovac D, Barnathan E, et al: Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res 18:3462-3469, 2012
23. Diaz LA Jr, Bardelli A: Liquid biopsies: Genotyping circulating tumor DNA. J Clin Oncol 32: 579-586, 2014
24. Thress KS, Brant R, Carr TH, et al: EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer 90:509-515, 2015
25. Xu T, Kang X, You X, et al: Cross-platform comparison of four leading technologies for detecting EGFR mutations in circulating tumor DNA from non-small cell lung carcinoma patient plasma. Theranostics 7:1437-1446, 2017
26. Gulley ML, Braziel RM, Halling KC, et al: Clinical laboratory reports in molecular pathology. Arch Pathol Lab Med 131:852-863, 2007
27. Li MM, Datto M, Duncavage EJ, et al: Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn 19:4-23, 2017
28. Clinical and Laboratory Standards Institute: Molecular Diagnostic Methods for Solid Tumors (Nonhematological Neoplasms), CLSI guidelineMM23 (ed 1). Wayne, PA, Clinical and Laboratory Standards Institute, 2015
29. Schiavon G, Hrebien S, Garcia-Murillas I, et al: Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med 7:313ra182, 2015
30. Oxnard GR, Thress KS, Alden RS, et al: Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol 34: 3375-3382, 2016
31. Krimmel JD, Schmitt MW, Harrell MI, et al: Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues. Proc Natl Acad Sci USA 113:6005-6010, 2016
32. Fernandez-Cuesta L, Perdomo S, Avogbe PH, et al: Identification of circulating tumor DNA for the early detection of small-cell lung cancer. EBioMedicine 10:117-123, 2016
33. Jaiswal S, Fontanillas P, Flannick J, et al: Agerelated clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371:2488-2498, 2014
34. Genovese G, Kähler AK, Handsaker RE, et al: Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371: 2477-2487, 2014
35. Xie M, Lu C, Wang J, et al: Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 20:1472-1478, 2014
36. Steensma DP, Bejar R, Jaiswal S, et al: Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126:9-16, 2015
37. Snyder MW, Kircher M, Hill AJ, et al: Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164:57-68, 2016
38. Sargent DJ, Conley BA, Allegra C, et al: Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23:2020-2027, 2005
39. Freidlin B, McShane LM, Polley MY, et al: Randomized phase II trial designs with biomarkers. J Clin Oncol 30:3304-3309, 2012
40. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446-1452, 2009
41. Douillard JY, Ostoros G, Cobo M, et al: Gefitinib treatment in EGFR mutated Caucasian NSCLC: Circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 9: 1345-1353, 2014
42. Kukita Y, Uchida J, Oba S, et al: Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data. PLoS One 8:e81468, 2013
43. Li X, Ren R, Ren S, et al: Peripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients. Transl Oncol 7: 341-348, 2014
44. Mok T, Wu YL, Lee JS, et al: Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res 21: 3196-3203, 2015
45. Oxnard GR, Paweletz CP, Kuang Y, et al: Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative nextgeneration genotyping of cell-free plasma DNA. Clin Cancer Res 20:1698-1705, 2014
46. Wei Z, Shah N, Deng C, et al: Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the disease. Springerplus 5:531, 2016
47. Sakai K, Horiike A, Irwin DL, et al: Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Sci 104:1198-1204, 2013
48. Wang Z, Chen R, Wang S, et al: Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFRTKI treatment in advanced NSCLC. PLoS One 9: e110780, 2014
49. Sacher AG, Paweletz C, Dahlberg SE, et al: Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol 2:1014-1022, 2016
50. Hao YX, Fu Q, Guo YY, et al: Effectiveness of circulating tumor DNA for detection of KRAS gene mutations in colorectal cancer patients: A metaanalysis. Onco Targets Ther 10:945-953, 2017
51. Jenkins S, Yang JC, Ramalingam SS, et al: Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non-small cell lung cancer. J Thorac Oncol 12:1061-1070, 2017
52. Schmiegel W, Scott RJ, Dooley S, et al: Bloodbased detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: Concordance of results from circulating tumor DNA and tissue-based RAS testing. Mol Oncol 11:208-219, 2017
53. Vidal J, Muinelo L, Dalmases A, et al: Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol 28:1325-1332, 2017
54. U.S. Food and Drug Administration: Medical Devices: cobas EGFR Mutation Test v2-P150047. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/ cfpma/pma.cfm?id=P150047
55. Redig AJ, Costa DB, TaibiM, et al: Prospective study of repeated biopsy feasibility and acquired resistance at disease progression in patients with advanced EGFR mutant lung cancer treated with erlotinib in a phase 2 trial. JAMA Oncol 2:1240-1242, 2016
56. Mok TS, Wu Y-L, Ahn M-J, et al: Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376:629-640, 2017
57. Remon J, Caramella C, Jovelet C, et al: Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA. Ann Oncol 28:784-790, 2017
58. Ascierto PA, Minor D, Ribas A, et al: Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 31:3205-3211, 2013
59. Baselga J, ImSA, Iwata H, et al: Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18:904-916, 2017
60. Newman AM, Bratman SV, To J, et al: An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20: 548-554, 2014
61. Paweletz CP, Sacher AG, Raymond CK, et al: Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clin Cancer Res 22: 915-922, 2016
62. Schwaederlé MC, Patel SP, Husain H, et al: Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma. Clin Cancer Res 23: 5101-5111, 2017
63. Oxnard GR: First validation, then discovery: Establishing truth from cfDNA genotyping. Presented at American Association for Cancer Research Annual Meeting, Washington, DC, April 4, 2017
64. Reinert T, Schøler LV, Thomsen R, et al: Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut 65:625-634, 2016
65. Diehl F, Schmidt K, Choti MA, et al: Circulating mutant DNA to assess tumor dynamics. Nat Med 14: 985-990, 2008
66. Marchetti A, Palma JF, Felicioni L, et al: Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients. J Thorac Oncol 10:1437-1443, 2015
67. Tie J, Kinde I, Wang Y, et al: Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol 26:1715-1722, 2015
68. Siravegna G, Mussolin B, Buscarino M, et al: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21: 795-801, 2015
69. Riva F, Bidard FC, Houy A, et al: Patientspecific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer. Clin Chem 63:691-699, 2017
70. Roschewski M, Dunleavy K, Pittaluga S, et al: Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol 16:541-549, 2015
71. Scherer F, Kurtz DM, Newman AM, et al: Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med 8:364ra155, 2016
72. Chen G, McQuade JL, Panka DJ, et al: Clinical, molecular, and immune analysis of dabrafenib-trametinib combination treatment for BRAF inhibitor-refractory metastatic melanoma: A phase 2 clinical trial. JAMA Oncol 2:1056-1064, 2016
73. Sorensen BS, Wu L, Wei W, et al: Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer 120:3896-3901, 2014
74. Chabon JJ, Simmons AD, Lovejoy AF, et al: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun 7:11815, 2016
75. Remon J, Menis J, Hasan B, et al: The APPLE trial: Feasibility and activity of AZD9291 (osimertinib) treatment on positive plasma T790M in EGFRmutant NSCLC patients. EORTC 1613. Clin Lung Cancer 18:583-588, 2017
76. Garćia-Saenz JA, Ayllón P, LaigM, et al: Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging. BMC Cancer 17:210, 2017
77. Conter V, Bartram CR, Valsecchi MG, et al: Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115:3206-3214, 2010
78. Oshiro C, Kagara N, Naoi Y, et al: PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients. Breast Cancer Res Treat 150:299-307, 2015
79. Tie J, Wang Y, Tomasetti C, et al: Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 8:346ra92, 2016
80. Garcia-Murillas I, Schiavon G, Weigelt B, et al: Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med 7: 302ra133, 2015
81. Olsson E, Winter C, George A, et al: Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med 7:1034-1047, 2015
82. Pietrasz D, Pécuchet N, Garlan F, et al: Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker. Clin Cancer Res 23:116-123, 2017
83. Abbosh C, Birkbak NJ, Wilson GA, et al: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545:446-451, 2017. doi: 10.1038/nature22364. [erratum in: Nature, 2017 Dec 20; PMID: 28445469]
84. Shaw JA, Page K, Blighe K, et al: Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res 22:220-231, 2012
85. Henry NL, Hayes DF, Ramsey SD, et al: Promoting quality and evidence-based care in earlystage breast cancer follow-up. J Natl Cancer Inst 106:dju034, 2014
86. Locker GY, Hamilton S, Harris J, et al: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313-5327, 2006
87. Rustin GJ, van der Burg ME, Griffin CL, et al: Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): A randomised trial. Lancet 376:1155-1163, 2010
88. Fizazi K, Tran N, Fein L, et al: Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377:352-360, 2017
89. James ND, de Bono JS, Spears MR, et al: Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377:338-351, 2017
90. Amant F, Verheecke M, Wlodarska I, et al: Presymptomatic identification of cancers in pregnant women during noninvasive prenatal testing. JAMA Oncol 1:814-819, 2015
91. Welch HG: Overdiagnosis and mammography screening. BMJ 339:b1425, 2009
92. Moyer VA; U.S. Preventive Services Task Force: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157:120-134, 2012
93. Chan KCA, Woo JKS, King A, et al: Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med 377:513-522, 2017